The PCAC review is July 23–24, 2026. Here is what that means for peptide access.

Two days at a federal advisory meeting are about to decide which peptides a US-licensed pharmacy will be allowed to put in a labelled vial with your name on it. The date is July 23–24, 2026. The location is FDA’s White Oak campus in Silver Spring. The forum coverage will be loud and mostly wrong. Here is the part that is actually load-bearing.

The committee meeting in July is reviewing seven peptides. A second meeting is queued for before the end of February 2027 to review five more. The vote is not a drug approval. Several peptides the marketplace lumps in as PCAC peptides are not on either docket at all — because they were already voted against, eighteen months ago, and the supplement world quietly stopped mentioning it.

What the July meeting actually is

PCAC stands for the Pharmacy Compounding Advisory Committee. It is a standing FDA advisory panel whose specific job is to recommend which substances belong on the Section 503A bulk drug substances list — the federal list of ingredients a licensed compounding pharmacy is allowed to use when filling a prescription for a named patient. The committee meets in public, takes outside testimony, deliberates, and votes. The FDA then writes a rule using that vote as input. The vote itself is a recommendation, not a regulation.

What makes the July meeting unusual is the batch shape of what’s in front of it. Twelve peptide compounds spread across two meetings, all of them currently sold off-label by research-chemical vendors, all of them being asked to defend an indication for compounding. This is not the FDA approving a drug. This is the FDA deciding whether a US pharmacist can legally make these compounds for a named patient with a prescription, for the indication the committee voted on.

That distinction matters more than the rest of the article combined, so it is worth labouring. A favourable PCAC vote in July is not the same as FDA approval. It does not mean a peptide has passed Phase 3 trials. It does not mean a doctor can prescribe it as a marketed drug. What a favourable vote means is that the compounding pathway opens for the indication on the record — and a US-licensed pharmacy can dispense it from a prescription written for that indication. An unfavourable vote effectively closes the compounding lane for that compound, and the off-label supply chain stays the only one available.

July 23 — four compounds

The April 2026 Federal Register notice 2026-07361 sets the agenda. On July 23 the committee evaluates four bulk drug substances. The FDA-reviewed indications below are read off the agency’s advisory-committee calendar page for the meeting. They are not the indications the off-label market sells.

BPC-157 — for ulcerative colitis. The compound the injury-recovery forums talk about is going to be evaluated for a gut indication, drawing on its mucosal-protection literature. The tendon and joint angle, which is what almost every research-chemical vendor markets it for, is not what the committee is voting on.

KPV — for wound healing and inflammatory conditions. A tripeptide fragment of alpha-melanocyte-stimulating hormone. The dual-indication framing is unusual and reflects the dual mechanism: KPV is studied both for skin repair and for downstream anti-inflammatory effects in the gut and elsewhere.

TB-500 — for wound healing. The thymosin-beta-4-derived peptide that anchors half the injury-recovery stack the forums build around BPC-157. The indication on the docket is narrower than the marketed use.

MOTs-C — for obesity and osteoporosis. This one is the sharpest example of indication drift. MOTs-C is sold across the longevity supplement market as a mitochondrial peptide for ageing. The FDA-reviewed indications are body composition and bone density. The longevity pitch and the regulatory record do not match.

July 24 — three more

Emideltide (DSIP) — for opioid withdrawal, chronic insomnia, and narcolepsy. Emideltide is the registered name; the underlying compound is the one most of the literature still calls delta sleep-inducing peptide. Three indications, all neurological.

Semax — for cerebral ischemia, migraine, and trigeminal neuralgia. A short heptapeptide developed in Russia in the 1980s for stroke recovery, now considered for the broader neurological set. Whatever the forums say about cognitive enhancement is not what the committee is voting on.

Epitalon — for insomnia. The longevity market sells this one as a telomere-biology compound. The FDA-reviewed indication is sleep. Again, the marketing pitch and the regulatory record are looking at different drugs.

The seven peptides on July 23–24 share a structural quality worth holding onto: the indication the committee will vote on is, in every case but TB-500, narrower or different from the indication the supplement market markets. A favourable vote opens the compounding pathway for the indication on the record. The off-label uses — the ones most buyers care about — sit outside what the vote covers.

What the February 2027 meeting is reviewing

The same April 2026 FDA action that established the July meeting also scheduled a second PCAC meeting before the end of February 2027. The exact date has not been published; the list of compounds has. Five more peptides will be reviewed: Dihexa acetate, LL-37, GHK-Cu, PEG-MGF, and Melanotan II.

The GHK-Cu entry is the most editorially interesting, and it is the cleanest demonstration of how route of administration writes the regulatory story. The FDA split GHK-Cu by route, and the two routes moved in opposite directions on the existing 503A bulks lists in the same action. Injectable GHK-Cu — the form the off-label market sells in vials — came off Category 2, the FDA’s do not compound / significant safety concerns list. That removal is the editorial event. The injectable route is no longer on the do-not-compound list. Non-injectable GHK-Cu — topical, the cosmetic copper-peptide format — was pulled out of Category 1, the under evaluation list that had been temporarily letting compounders make it under FDA enforcement discretion. Topical GHK-Cu therefore lost a safe harbor it used to have. Both forms are scheduled for the February consultation; the route distinction is what matters.

Anyone writing about GHK-Cu and waving toward “PCAC” needs to do this carefully. On the docket hides which docket, which wave, which route, and which direction. Compressing it is how the misinformation spreads.

The peptides that are not on either docket

This is the part of the regulatory picture most forum coverage gets wrong. Several compounds the supplement market currently labels as PCAC peptides are not on the July docket, are not on the February docket, and are not still awaiting review. They have already had their PCAC review and they lost.

CJC-1295 was evaluated at the December 4, 2024 PCAC meeting. The committee voted against inclusion on the 503A bulks list. Ipamorelin was evaluated at the October 29, 2024 meeting and the committee voted against. AOD-9604 was evaluated at the December 4 meeting and the committee voted against. Thymosin alpha-1 was evaluated at the same December meeting and the committee voted against — with the additional structural complication that Tα1 sits under biologics regulation, not the small-molecule 503A framework most other peptides ride.

The FDA’s standard reasoning across those four votes was a consistent triplet: insufficient human safety data, mechanistic concerns about unintended endocrine effects, and lack of reproducible efficacy data outside small or open-label trials. None of those four compounds are getting another shot at PCAC in 2026 or 2027. The framing not on the upcoming dockets is technically correct and substantively misleading. What it actually means is PCAC already heard the case and decided against. Anyone writing or buying around those four ought to know.

The other shape — peptides not on the dockets and not previously voted on — covers sermorelin (which sits under a pre-existing compounding framework after the Geref withdrawals in 2009), selank (not scheduled, not previously voted on), tesamorelin (already an approved drug — Egrifta WR — so it can’t be on a docket meant for unapproved substances), and PT-141 (approved as Vyleesi for HSDD, with its own regulatory path). These four are outside the current PCAC question for structural reasons, not because the committee said no.

What a PCAC vote does not establish

A favourable PCAC recommendation in July would not give BPC-157 FDA approval as a marketed drug. The marketed-drug pathway runs through Investigational New Drug applications, Phase 1, Phase 2, and Phase 3 randomised trials, then a New Drug Application. None of that has been completed for any of the twelve peptides under review across the two waves, and none will be by July 2026 or February 2027.

What a favourable vote does establish is that the substance may be dispensed in a compounded prescription by a US-licensed pharmacy under Section 503A, for the specific indication the committee evaluated — not the use the supplement market promotes. A compounded BPC-157 prescription for ulcerative colitis would sit on a clear regulatory floor. A compounded BPC-157 prescription for a torn shoulder would be the supervising physician’s call as off-label use of a compounded drug — a greyer position than the headline implies.

What an unfavourable vote does is close the compounding lane for that compound. The off-label supply chain — research-chemical vendors, vials labelled not for human consumption, no prescription, no supervising physician — is what is left. That is the present situation for the four compounds that already had their vote in 2024. It is the future for whichever compounds the July and February meetings vote against.

What to actually watch in July

Three things are worth reading off the meeting in real time. First, the indication-vs-indication question — whether the committee’s discussion stays narrowly on the FDA-reviewed indication on the record, or whether it broadens out to the off-label uses driving most demand. Forum coverage will conflate the two. The committee will not. Whichever indication the vote attaches to is the one a future prescription has to match.

Second, the safety record the FDA staff puts on the record. For most of these compounds the human evidence is thin enough to fit on a small chart. Some are first-in-class, some are decades-old Soviet-era compounds with a different evidence tradition behind them. The committee’s read of how thin is how thin matters more than the marketing volume around any single compound.

Third, the vote splits. PCAC votes are recorded by member. A unanimous vote signals the FDA staff position carried; a split vote leaves room for the agency to write the rule either way. A 12-2 vote against on one peptide and an 8-6 vote in favour on another mean different things for the rulemaking process that follows, even if the public summary collapses both into a verdict.

After the vote — and this is where the timeline matters — the FDA still has to write the rule. A favourable PCAC recommendation in July does not become a prescription you can fill in August. The rulemaking process takes months at minimum and often longer. The vote sets direction. The rule sets access.

After July: what changes for the seven

Right now the only supply chain for the twelve peptides under PCAC review runs through research-chemical sites — vials labelled not for human consumption, no third-party testing, no prescription, no supervising physician. The July and February meetings are the formal regulatory gates between that supply chain and a different one: a US physician’s prescription, a US-licensed compounding pharmacy, a named indication on the label.

Whichever peptides survive the votes on July 23 and 24 are the ones a US-licensed pharmacy will eventually be allowed to compound. The version of that supply chain — a doctor’s prescription, a licensed pharmacy, a third-party-tested vial — is the one Wolverine Health is being built to deliver. Watching the docket, not standing in front of it.

Join the waitlist for a heads-up the moment the regulated version of a peptide you are tracking is actually available.